Akonni Biosystems Awarded $3.2M National Institutes of Health (NIH) Grant to Combine Gel-drop Microarray and PCR Technology for Rapid, Low-cost Influenza Detection
Published: Dec 01, 2009
FREDERICK, Md.--(BUSINESS WIRE)--Akonni Biosystems, a molecular diagnostics (MDx) company focused on providing rapid and highly scalable solutions for infectious disease testing, today announced receipt of a $3.2M Phase II SBIR grant from the National Institutes of Health (NIH). The award will enable Akonni to combine PCR with its existing TruArray(R) gel-drop microarray in a single chamber, closed-amplicon system, and field test it for the detection of influenzas A and B and their antigenic subtypes, including antiviral resistant types. This grant is based on the successful completion of an earlier Phase I SBIR, and has as a goal the production of commercial products for clinical and research laboratories.